Unveiling the Core Fundamentals of Sarepta Therapeutics (SRPT)

By Emilio Sanchez • Wednesday, March 19 09:53 • Permanent Link

Shares of Pharmaceutical company Sarepta Therapeutics climbed 5.8% this morning. Here are some quick facts to get you started if you are interested in the stock:

Sarepta Therapeutics has logged a -41.7% 52 week change, compared to 7.5% for the S&P 500
SRPT has an average analyst rating of buy and is -55.36% away from its mean target price of $174.27 per share
Its trailing earnings per share (EPS) is $2.34, which brings its trailing Price to Earnings (P/E) ratio to 33.2. The Health Care sector's average P/E ratio is 26.07
The company's forward earnings per share (EPS) is $11.45 and its forward P/E ratio is 6.8
The company has a Price to Book (P/B) ratio of 4.93 in contrast to the Health Care sector's average P/B ratio is 3.53
The current ratio is currently 4.0, which consists in its liquid assets divided by any liabilities due within in the next 12 months
SRPT has reported YOY quarterly earnings growth of 245.2% and gross profit margins of 0.4%
The company's free cash flow for the last fiscal year was $-577099000 and the average free cash flow growth rate is -5.1%
Sarepta Therapeutics's revenues have an average growth rate of 29.5% with operating expenses growing at 14.4%. The company's current operating margins stand at -21.5%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.